Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHJ002 dose escalation in pediatric myopia
NCT04928144Phase 1Completed
- Sponsor
- Sunhawk Vision Biotech, Inc.
- Start
- Jul 2021
- Primary completion
- Sep 2021
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of SHJ002 in myopia (2 cohorts), sponsored by Sunhawk Vision Biotech, Inc. Primary endpoints: Change from baseline in best corrected visual acuity at 28 days and Incidence of Adverse Events at 28 days. Started Jul 2021; status: completed.
02
Drugs
SHJ002
03
Conditions
myopia
Beyond the preview
Go deeper on NCT04928144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04928144.